Eloxx Pharmaceuticals | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Eloxx Pharmaceuticals | NT 10-K: Others
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aggarwal Sumit
Eloxx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Androski Lindsay
Eloxx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Rubin Steven D
Eloxx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Walts Alan Edmund
Eloxx Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
Eloxx Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 8-K: Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals: Q3 2023 Earnings Report
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 8-K: Current report
Eloxx Pharmaceuticals | 424B5: Prospectus
Eloxx Pharmaceuticals | 8-K: Current report
No Data